DBV TECHNOLOGIES (EPA:DBV) | WebDisclosure

Basculer en Français

8295	Companies
114863	Keywords
55304	Articles
62446	Press releases

Home
Companies
DBV TECHNOLOGIES

BRIEF

published on 05/09/2024 at 22:35, 6 months 11 days ago

DBV Technologies announces its participation in two investor conferences in May

DBV Technologies Food Allergy JMP Life Sciences HC Wainwright BioConnect Conference Webcast
BRIEF

published on 05/09/2024 at 22:35, 6 months 11 days ago

DBV Technologies annonce sa participation à deux conférences investisseurs en mai

DBV Technologies Allergies Alimentaires JMP Sciences De La Vie H.C. Wainwright BioConnect Webdiffusion Conférence
PRESS RELEASE

published on 05/09/2024 at 22:30, 6 months 11 days ago

DBV Technologies to Participate in Upcoming Investor Conferences
DBV Technologies to participate in two upcoming investor conferences in May, presenting its clinical-stage biopharmaceutical developments. Learn more about their innovative treatment options

Investor Conferences Biopharmaceutical DBV Technologies Food Allergies Immunologic Conditions
PRESS RELEASE

published on 05/09/2024 at 22:30, 6 months 11 days ago

Participation de DBV Technologies aux conférences investisseurs en mai
DBV Technologies participera aux conférences investisseurs en mai pour présenter les options de traitement des allergies alimentaires et conditions immunologiques, notamment avec sa plateforme Viaskin. Détails des événements disponibles sur le site web

Traitement Conférences Investisseurs DBV Technologies Allergies Alimentaires Viaskin
BRIEF

published on 05/07/2024 at 22:35, 6 months 13 days ago

DBV Technologies publie ses résultats financiers du premier trimestre 2024 et fait le point sur ses activités

Résultats Financiers DBV Technologies Efficacité Viaskin Peanut Nomination Affaires Réglementaires Évolution Trésorerie Essai Clinique VITESSE
BRIEF

published on 05/07/2024 at 22:35, 6 months 13 days ago

DBV Technologies publishes its financial results for the first quarter of 2024 and provides an update on its activities

DBV Technologies Financial Results Effectiveness Viaskin Peanut Regulatory Affairs Appointment Cash Flow Evolution VITESSE Clinical Trial
PRESS RELEASE

published on 05/07/2024 at 22:30, 6 months 13 days ago

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update
DBV Technologies reports Q1 2024 financial results and business update, with VITESSE enrollment progress, appointment of Chief Regulatory Officer, and $101.5 million cash balance

Financial Results Q1 2024 DBV Technologies VITESSE Enrollment Chief Regulatory Officer
PRESS RELEASE

published on 05/07/2024 at 22:30, 6 months 13 days ago

DBV Technologies publie ses résultats financiers du premier trimestre 2024 et fait le point sur ses activités
DBV Technologies publie ses résultats financiers du premier trimestre 2024, recrutement en bonne voie pour VITESSE, nomination de Robert Pietrusko comme Directeur des Affaires Règlementaires

Résultats Financiers Affaires Réglementaires DBV Technologies VITESSE Robert Pietrusko

Accesswire

Published on 11/21/2024 at 12:00, 1 hour 9 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 1 hour 9 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 39 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 3 hours 6 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 3 hours 9 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 34 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 54 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 3 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 9 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 39 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 11 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 11 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 11 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 17 hours 2 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 49 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE